Inari Medical (NARI) Expected to Announce Earnings on Wednesday

Inari Medical (NASDAQ:NARI) is projected to post its quarterly earnings results before the market opens on Wednesday, February 26th. Analysts expect Inari Medical to post earnings of ($0.01) per share and revenue of $160.70 million for the quarter.

Inari Medical Stock Performance

NARI opened at $79.97 on Monday. Inari Medical has a one year low of $36.73 and a one year high of $79.99. The company has a market cap of $4.68 billion, a P/E ratio of -59.24 and a beta of 1.02. The business’s 50-day simple moving average is $71.49 and its 200-day simple moving average is $55.54.

Insider Activity

In other news, Director William Hoffman sold 60,000 shares of the firm’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $55.66, for a total value of $3,339,600.00. Following the completion of the sale, the director now directly owns 441,233 shares of the company’s stock, valued at $24,559,028.78. This trade represents a 11.97 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Andrew Hykes sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $55.29, for a total value of $165,870.00. Following the completion of the sale, the chief executive officer now directly owns 439,310 shares of the company’s stock, valued at $24,289,449.90. This represents a 0.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 263,000 shares of company stock valued at $15,599,470 in the last three months. 10.60% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Truist Financial increased their price objective on Inari Medical from $50.00 to $63.00 and gave the company a “hold” rating in a report on Wednesday, December 18th. William Blair reissued a “market perform” rating on shares of Inari Medical in a research report on Tuesday, January 7th. Oppenheimer initiated coverage on Inari Medical in a research report on Tuesday, December 17th. They issued an “outperform” rating and a $75.00 target price for the company. Canaccord Genuity Group reaffirmed a “hold” rating and set a $80.00 price objective (up from $74.00) on shares of Inari Medical in a research report on Tuesday, January 7th. Finally, Robert W. Baird reaffirmed a “neutral” rating and set a $80.00 price objective (down from $81.00) on shares of Inari Medical in a research report on Tuesday, January 7th. Twelve analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, Inari Medical currently has a consensus rating of “Hold” and a consensus target price of $68.00.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.